2024-09-16 - Analysis Report
## JNJ Stock Analysis: A Comprehensive Overview

**Company Overview:** Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company known for its diverse range of healthcare products and solutions.

**1. Performance Comparison and Relative Strength:**

JNJ has yielded a cumulative return of 19.53%, significantly lagging behind the S&P 500 (VOO) which has delivered a return of 88.73%. This underperformance is evident in the substantial negative divergence of -69.2, representing a 13.56% relative position within its historical range. 

**2. Recent Price Fluctuation:**

JNJ's current closing price is $165.52. The stock is currently trading slightly above its 5-day moving average ($165.79) but below its 20-day ($164.08) and 60-day ($157.13) moving averages, suggesting a potential short-term consolidation phase.

**3. Technical Indicators Analysis:**

* **RSI (54.3):** JNJ's RSI indicates that the stock is currently trading in the neutral territory, neither oversold nor overbought.
* **PPO (-0.19):** The negative PPO value suggests potential downward momentum, though it's not significantly pronounced.
* **Delta_Previous_Relative_Divergence (2.14):** The positive value indicates that the recent 20-day relative divergence has been increasing, suggesting a potential shift towards a short-term upward trend.
* **Expected_Return (11.87%):**  JNJ's expected return over the next 5 years is 11.87%, signifying a potentially lucrative long-term investment opportunity. 

**4. Recent Earnings Performance and Outlook:**

**Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | $22.45 Billion |
| 2024-05-01 | 1.35 | $21.38 Billion |
| 2024-02-16 | 1.68 | $21.39 Billion |
| 2023-10-27 | 10.32 | $21.35 Billion |
| 2024-02-16 | 10.32 | $21.35 Billion |

**Analysis:** While we lack information about the earnings estimates for the latest quarter (2024-07-25), JNJ's consistent revenue performance, coupled with its strong position in the healthcare market, points towards a robust and stable financial foundation. 

**5. Conclusion:**

JNJ is a well-established, diversified company with a strong track record in the healthcare sector. While its recent performance lags behind the broader market, the positive indicators like its expected return and increasing relative divergence suggest potential for future growth. Investors seeking long-term stability and dividend income might find JNJ an attractive investment. However, its recent underperformance and neutral technical indicators warrant careful monitoring of upcoming earnings announcements and market trends. 
